Share on LinkedInShare on LinkedIn

ARTICLE · 28 DECEMBER 2020

Patent Prior Approval Analysis In Brazil – ANVISA's Role Clarified

Four recently published Guidelines shed light on ANVISA's procedures related to prior approval analysis of patent applications

BrazilIntellectual Property

Four recently published Guidelines shed light on ANVISA's procedures related to prior approval analysis of patent applications

In November 2020, the Brazilian Health Surveillance Agency (Brazilian FDA – "ANVISA") published four guidelines disclosing the procedures adopted by ANVISA to analyze prior approval of patent applications related to pharmaceutical products and processes.

This is the first time ANVISA brings into view details on how the Agency examines patent applications remitted by the Brazilian Patent Office (BRPTO) for compliance with Article 229-C1 of the Brazilian Patent Statute.

Since the agreement reached by ANVISA and the BRPTO in 2017 (Joint Ordinance 01/2017), ANVISA can only deny prior approval based on public health matters. However, if the application relates to therapeutic matters of interest for the Brazilian health policies, ANVISA can perform a patentability analysis, which will be considered by the BRPTO as a third-party observation

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from